Cancer Biomarkers for Integrative Oncology

被引：5

作者：

Ganguly, Aniruddha ^{[1
]}

Frank, David ^{[2
,3
]}

Kumar, Nagi ^{[4
]}

Cheng, Yung-Chi ^{[5
]}

Chu, Edward ^{[6
]}

机构：

[1] NCI, Canc Diag Program, Div Canc Treatment & Diag, NIH, 9609 Med Ctr Dr,Rm 4-W438, Rockville, MD 20850 USA

[2] Dana Farber Canc Inst, Boston, MA 02215 USA

[3] Harvard Med Sch, Boston, MA 02215 USA

[4] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[5] Yale Univ, Sch Med, Yale Canc Ctr, Dept Pharmacol,Dev Therapeut Program, 333 Cedar St, New Haven, CT 06510 USA

[6] Univ Pittsburgh, UPMC Hillman Canc Ctr, Sch Med, Dept Med,Canc Therapeut Program, Pittsburgh, PA 15232 USA

来源：

CURRENT ONCOLOGY REPORTS | 2019年 / 21卷 / 04期

关键词：

Biomarker; Cancer complementary and alternative medicine (CAM); Integrative oncology; Cancer diagnostics; Anti-cancer natural product; Anti-cancer herbal medicine; CELL-CYCLE ARREST; NF-KAPPA-B; BLADDER-CANCER; PHASE-I; DIETARY ISOTHIOCYANATES; ALLYL ISOTHIOCYANATE; BROCCOLI SPROUTS; CHINESE MEDICINE; NATURAL-PRODUCT; TUMOR-GROWTH;

D O I：

10.1007/s11912-019-0782-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of ReviewThere has been an increasing interest in using complementary and alternative medicine (CAM) approaches to treat cancer. It is therefore relevant and timely to determine if CAM biomarkers can be identified and developed to guide cancer diagnosis and treatment. Herein, we review the status of cancer biomarkers in CAM research and treatment to stimulate further research in this area.Recent FindingsStudies on promising anti-cancer natural products, such as PHY906, honokiol, bryostatin-1, and sulforaphane have demonstrated the existence of potential cancer biomarker(s). Additional studies are required to further develop and ultimately validate these biomarkers that can predict clinical activity of the anti-cancer natural products used alone or in combination with chemotherapeutic agents.SummaryA systematic approach is needed to identify and develop CAM treatment associated biomarkers and to define their role in facilitating clinical decision-making. The expectation is to use these biomarkers in determining potential options for CAM treatment, examining treatment effects and toxicity and/or clinical efficacy in patients with cancer.

引用

页数：13

共 81 条

[51] Cell Cycle Arrest by Transforming Growth Factor β1 near G1/S Is Mediated by Acute Abrogation of Prereplication Complex Activation Involving an Rb-MCM Interaction [J].